Anthera Pharmaceuticals, Inc. (ANTH)

[Paulieme]

Anthera Pharmaceuticals Inc (ANTH) PT Lowered to $11.00
February 20th, 2016 ----- Anthera Pharmaceuticals Inc (NASDAQ:ANTH) had its target price dropped by equities research analysts at Citigroup Inc. from $15.00 to $11.00 in a report released on Friday, StockTargetPrices.com reports. Citigroup Inc.’s price objective would indicate a potential upside of 263.04% from the company’s previous close.

An institutional investor recently raised its position in Anthera Pharmaceuticals stock. Sio Capital Management LLC raised its position in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) by 61.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,378,443 shares of the biopharmaceutical company’s stock after buying an additional 522,371 shares during the period. Anthera Pharmaceuticals makes up 2.8% of Sio Capital Management LLC’s holdings, making the stock its 12th largest position. Sio Capital Management LLC owned 3.46% of Anthera Pharmaceuticals worth $6,396,000 as of its most recent SEC filing.

Other analysts also recently issued reports about the company. Jefferies Group restated a “buy” rating and set a $9.00 price objective on shares of Anthera Pharmaceuticals in a report on Friday. Zacks Investment Research downgraded Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $10.45.--http://www.owler.com/iaApp/article/56c965e1e4b075e7a6489d48.htm?utm_source=twitter&utm_medium=social&utm_campaign=sectorNews_Pharmaceuticals